Yara Abdou, MD, on the Advantages of CAR Macrophages in Solid Tumors

The assistant professor of oncology at UNC School of Medicine discussed the first-in-human study being conducted with CT-0508.

"Another advantage of macrophages is that they're circulating cells and they migrate out of the blood within hours after the infusion. Therefore, the pro-inflammatory cytokines they released are not causing sustained elevation of cytokines in the blood and we don't see severe cytokine release syndrome with our macrophage therapy.”

A phase 1, first-in-human study is evaluating the safety, tolerability and preliminary efficacy of an anti-human epidermal growth factor receptor 2 (HER2) chimeric antigen receptor (CAR) macrophage therapy, CT-0508 (Carisma Therapeutics) in solid tumors with HER2 overexpression.

An overview of the study was presented at the American Society of Gene and Cell Therapy 25th Annual Meeting, May 16-19, 2022, in Washington, DC.by Yara Abdou, MD, assistant professor of oncology at University of North Carolina School of Medicine.

CGTLive spoke with Abdou to learn more about CT-0508 and how CAR macrophage therapies address the challenges of traditional CAR T-therapies in solid tumors. She discussed the progress of the first-in-human, phase 1 study in HER2+ solid tumors.

Stay up to date with coverage from ASGCT 2022 by clicking here.

REFERENCE
Abdou Y, Yuan Y, Ueno NT, et al. A phase 1, first in human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Presented at: ASGCT 25th Annual Meeting, May 16-19, 2022; Washington DC. Abstract #805